Publications by authors named "D Carlin"

Background: The National Institute of Environmental Health Sciences (NIEHS) continues to prioritize research to better understand the health effects resulting from exposure to mixtures of chemical and nonchemical stressors. Mixtures research activities over the last decade were informed by expert input during the development and deliberations of the 2011 NIEHS Workshop "Advancing Research on Mixtures: New Perspectives and Approaches for Predicting Adverse Human Health Effects." NIEHS mixtures research efforts since then have focused on key themes including ) prioritizing mixtures for study, ) translating mixtures data from and studies, ) developing cross-disciplinary collaborations, ) informing component-based and whole-mixture assessment approaches, ) developing sufficient similarity methods to compare across complex mixtures, ) using systems-based approaches to evaluate mixtures, and ) focusing on management and integration of mixtures-related data.

View Article and Find Full Text PDF

The heart, which is the first organ to develop, is highly dependent on its form to function. However, how diverse cardiac cell types spatially coordinate to create the complex morphological structures that are crucial for heart function remains unclear. Here we integrated single-cell RNA-sequencing with high-resolution multiplexed error-robust fluorescence in situ hybridization to resolve the identity of the cardiac cell types that develop the human heart.

View Article and Find Full Text PDF

Methionine is an essential proteinogenic amino acid, but its excess can lead to deleterious effects. Inborn errors of methionine metabolism resulting from loss of function in cystathionine β-synthase (CBS) cause classic homocystinuria (HCU), which is managed by a methionine-restricted diet. Synthetic biotics are gastrointestinal tract-targeted live biotherapeutics that can be engineered to replicate the benefits of dietary restriction.

View Article and Find Full Text PDF
Article Synopsis
  • Gefurulimab (ALXN1720) is a bispecific antibody designed for subcutaneous treatment of chronic disorders linked to the activation of the terminal complement pathway by blocking the breakdown of complement component 5 (C5).
  • It consists of specialized antibody fragments derived from llamas and humans that bind tightly to C5 and human serum albumin (HSA), enabling it to inhibit complement activity effectively in lab assays.
  • Structural studies indicate that gefurulimab obstructs C5's interaction with its activating convertase, suggesting it is a strong candidate for treating complement-mediated disorders.
View Article and Find Full Text PDF

This research examines the prevalence of research software as independent records of output within UK academic institutional repositories (IRs). There has been a steep decline in numbers of research software submissions to the UK's Research Excellence Framework from 2008 to 2021, but there has been no investigation into whether and how the official academic IRs have affected the low return rates. In what we believe to be the first such census of its kind, we queried the 182 online repositories of 157 UK universities.

View Article and Find Full Text PDF